Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates high-contrast NIR-II imaging of EGFR-overexpressing tumors using engineered extracellular vesicles, indicating promising noninvasive cancer diagnostic utility.
Fluorescence imaging in the second near-infrared (NIR-II) region possesses numerous advantages and shows a promising future in cancer imaging. Developing tumor-targeting NIR-II fluorescent probes with both high fluorescence brightness and favorable biocompatibility promotes the clinical applications of NIR-II fluorescence imaging technology. Herein, we used natural small extracellular vesicles with a size of 140 nm as a nanoplatform to integrate water-soluble NIR-II fluorescent CH1055-PEG molecules and epidermal growth factor receptor (EGFR)-targeting GE11 peptides to prepare a bright and biocompatible NIR-II fluorescent nanoprobe sEV-CH1055-GE11 for in vivo high-contrast imaging of tumors with high EGFR expression. Increased amounts of CH1055-PEG and nanoprobe modification with GE11 peptides enabled imaging with high NIR-II fluorescence brightness and enhanced tumor-targeting capability. In in vivo imaging, sEV-CH1055-GE11 achieved extremely high-contrast imaging of tumors with high EGFR expression. The tumor-to-background ratio surpassed the Rose criterion of 5 at 48 h post-injection and reached 10.43 at 72 h post-injection. Cell viability, blood analysis, and hematoxylin–eosin staining assays indicated that this nanoprobe possessed favorable biocompatibility. This study demonstrates the potential applications of sEV-CH1055-GE11 in NIR-II fluorescence imaging of tumors with high EGFR expression.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: